California 2025-2026 Regular Session

California Senate Bill SB418

Introduced
2/18/25  
Refer
2/26/25  
Report Pass
4/10/25  
Refer
3/27/25  
Report Pass
4/10/25  
Report Pass
4/23/25  
Refer
4/10/25  
Report Pass
4/23/25  
Report Pass
4/10/25  
Refer
4/24/25  
Refer
4/10/25  
Refer
4/24/25  
Refer
4/10/25  
Engrossed
5/28/25  
Report Pass
4/23/25  
Refer
6/5/25  
Refer
4/24/25  
Report Pass
4/23/25  
Refer
4/24/25  
Report Pass
4/23/25  
Refer
6/23/25  
Refer
4/24/25  
Report Pass
7/2/25  
Refer
7/2/25  
Report Pass
7/8/25  
Refer
7/9/25  

Caption

Health care coverage: prescription hormone therapy and nondiscrimination.

Impact

If passed, SB 418 would significantly alter existing laws related to health care coverage. It would require Medi-Cal managed care plans to include hormone therapies as covered benefits, prohibiting insurers from imposing restrictions that limit these supplies to less than a year. The bill would also enhance protections against discrimination based on various personal characteristics—including race, color, sex, and gender identity—ensuring equitable access to health care services for all Californians. This legislation is particularly aimed at ensuring transgender individuals and other marginalized groups can access essential medical care without discrimination or undue barriers.

Summary

Senate Bill 418, authored by Senator Menjivar, focuses on expanding health care coverage specifically related to prescription hormone therapy and ensuring nondiscriminatory practices in health service plans and health insurance policies. The bill obligates health care service plans and insurers to provide coverage for up to a 12-month supply of FDA-approved prescription hormone therapies necessary for individuals undergoing treatment. This important legislation aims to ensure that those who need these therapies have better access and that coverage will not be unduly restricted by insurance providers.

Sentiment

The general sentiment surrounding SB 418 is one of urgency and support within the context of rising challenges faced by transgender individuals and others requiring hormone therapy in several states. Advocates see this bill as a necessary step towards protecting health care access amid concerns about potential federal policies that may restrict gender-affirming care. There are, however, concerns from some segments questioning the implications on medical insurance structures and the extent of the mandated coverage, leading to a mixed sentiment in broader health care circles.

Contention

Notable points of contention include the balance between ensuring comprehensive care while managing costs for insurers and health care providers. Critics argue that such mandates could lead to higher insurance premiums or reduced options for patients if insurers choose to limit the coverage they provide in other areas. Proponents counter that access to hormone therapy is essential for mental and physical well-being, highlighting the broad implications for communities impacted by discrimination in health care settings. The urgency of the bill reflects ongoing national discussions about health equity and the rights of transgender and non-binary individuals.

Companion Bills

No companion bills found.

Previously Filed As

CA AB2467

Health care coverage for menopause.

CA SB70

Prescription drug coverage.

CA AB2169

Prescription drug coverage: dose adjustments.

CA SB729

Health care coverage: treatment for infertility and fertility services.

CA SB516

Health care coverage: prior authorization.

CA SB598

Health care coverage: prior authorization.

CA AB1060

Health care coverage: naloxone hydrochloride.

CA SB427

Health care coverage: antiretroviral drugs, drug devices, and drug products.

CA SB621

Health care coverage: biosimilar drugs.

CA AB3260

Health care coverage: reviews and grievances.

Similar Bills

No similar bills found.